Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial
Raches Ella(Bharat Biotech (India)), Pragya D. Yadav, Satyajit Mohapatra(Sri Ramachandra Medical Centre), Gajanan Sapkal(ICMR-National Institute of Virology), Suman Kanungo(Indian Council of Medical Research), Sai Prasad(Bharat Biotech (India)), Varsha Potdar(ICMR-National Institute of Virology), Savita Verma(Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences), Anil Kumar Pandey(ESIC Hospital), Raghvendra Gumashta(People’s University), Pajanivel Ranganadin(Mahatma Gandhi Medical College and Research Institute), Chandramani Singh(All India Institute of Medical Sciences), William C. Blackwelder, Sagar Vivek Redkar, Krishna Mohan Vadrevu(Bharat Biotech (India)), Samiran Panda(Indian Council of Medical Research), Krishna M. Ella(Bharat Biotech (India)), Priya Abraham(ICMR-National Institute of Virology), Vamshi Sarangi(Bharat Biotech (India)), Balram Bhargava(Indian Council of Medical Research), Laxmi Kumari, Shameem Mohammad(Aligarh Muslim University), Nivedita Gupta(Indian Council of Medical Research), Sanjay Rai(All India Institute of Medical Sciences), Manish Multani, Prabhakar Reddy(Nizam's Institute of Medical Sciences), Siddarth Reddy(Bharat Biotech (India)), Parul Bhatt(B.J. Medical College)
Cited by 80
Related Papers
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
|Microorganisms|2021|658
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
|The Lancet Infectious Diseases|2021|364
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
|The Lancet|2021|361
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
|bioRxiv (Cold Spring Harbor Laboratory)|2021|268